Efficacy, safety and immunological profile of combining rituximab with belimumab for adults with persistent or chronic immune thrombocytopenia: results from a prospective phase 2b trial
Matthieu Mahévas, Imane Azzaoui, Etienne Crickx, Florence Canoui-Poitrine, Delphine Gobert, Laetitia Languille, Nicolas Limal, Constance Guillaud, Laure Croisille, Mohamed Jeljeli, Fréderic Batteux, Samia Baloul, Olivier Fain, France Pirenne, Jean-Claude Weill, Claude-Agnès Reynaud, Bertrand Godeau, Marc Michel, Matthieu Mahévas, Imane Azzaoui, Etienne Crickx, Florence Canoui-Poitrine, Delphine Gobert, Laetitia Languille, Nicolas Limal, Constance Guillaud, Laure Croisille, Mohamed Jeljeli, Fréderic Batteux, Samia Baloul, Olivier Fain, France Pirenne, Jean-Claude Weill, Claude-Agnès Reynaud, Bertrand Godeau, Marc Michel
Abstract
B-cell activating factor may be involved in the failure of B-cell depleting therapy with rituximab in immune thrombocytopenia (ITP) by promoting the emergence of splenic long-lived plasma cells. From results obtained in mouse models, we hypothesized that combining rituximab with sequential injections of belimumab could increase the rate of response at one year in patients with persistent or chronic ITP by preventing the emergence of these long-lived plasma cells. The study was a single-center, single arm, prospective phase 2b trial (RITUX-PLUS, NCT03154385) investigating the safety and efficacy of rituximab given at a fixed dose of 1,000 mg, two weeks apart, combined with five infusions of belimumab, 10 mg/kg at week 0 (W0)+2 days, W2+2 days, W4, W8 and W12 for adults with primary persistent or chronic ITP. The primary endpoint was the total number of patients achieving an overall response (complete response + response) at W52 according to a standard definition. In total, 15 non-splenectomized adults, nine (60%) with persistent IPT and six (40%) with chronic ITP, were included. No severe adverse event, infection, or severe hypogammaglobulinemia was observed. Thirteen patients achieved an initial overall response. At W52, 12 (80%) patients achieved an overall response, including ten (66.7%) with complete response. When compared with a cohort of patients receiving rituximab alone, the kinetics of B-cell repopulation appeared similar, but the number of circulating T follicular helper cells was significantly decreased with belimumab combination therapy. Combining rituximab and belimumab seems a promising strategy in ITP, with high efficacy and acceptable safety.
Figures
References
- Cines DB, Cuker A, Semple JW. Pathogenesis of immune thrombocytopenia. Presse Médicale Paris Fr. 1983 2014;43(4 Pt 2):e49-59.
- Audia S, Mahévas M, Samson M, Godeau B, Bonnotte B.Pathogenesis of immune thrombocytopenia. Autoimmun Rev. 2017;16(6):620-632.
- Moulis G, Germain J, Comont T, et al. . Newly diagnosed immune thrombocytopenia adults: Clinical epidemiology, exposure to treatments, and evolution. Results of the CARMEN multicenter prospective cohort. Am J Hematol. 2017;92(6):493-500.
- Khellaf M, Charles-Nelson A, Fain O, et al. . Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. Blood. 2014;124(22):3228-3236.
- Chugh S, Darvish-Kazem S, Lim W, et al. . Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis. Lancet Haematol. 2015;2(2):e75-81.
- Mahévas M, Patin P, Huetz F, et al. . B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells. J Clin Invest. 2013;123(1):432-442.
- Audia S, Rossato M, Santegoets K, et al. . Splenic TFH expansion participates in B-cell differentiation and antiplatelet-antibody production during immune thrombocytopenia. Blood. 2014;124(18):2858-2866.
- Mahévas M, Michel M, Vingert B, et al. . Emergence of long-lived autoreactive plasma cells in the spleen of primary warm auto-immune hemolytic anemia patients treated with rituximab. J Autoimmun. 2015;62:22-30.
- Mahévas M, Michel M, Weill J-C, Reynaud C-A. Long-lived plasma cells in autoimmunity: lessons from B-cell depleting therapy. Front Immunol. 2013;4:494.
- Thai L-H, Le Gallou S, Robbins A, et al. . BAFF and CD4+T cells are major survival factors for long-lived splenic plasma cells in a B-cell-depletion context. Blood. 2018; 131(14):1545-1555.
- Mackay F, Schneider P.Cracking the BAFF code. Nat Rev Immunol. 2009;9(7):491-502.
- Rodeghiero F, Stasi R, Gernsheimer T, et al. . Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386-2393.
- Grabar S, Groh M, Bahuaud M, et al. . Pneumococcal vaccination in patients with systemic lupus erythematosus: A multicenter placebo-controlled randomized double-blind study. Vaccine. 2017;35(37): 4877-4885.
- Anolik JH, Friedberg JW, Zheng B, et al. . B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. Clin Immunol Orlando Fla. 2007;122(2):139-145.
- Sanz I, Wei C, Jenks SA, et al. . Challenges and opportunities for consistent classification of human B cell and plasma cell populations. Front Immunol. 2019; 10:2458.
- Locci M, Havenar-Daughton C, Landais E, et al. . Human circulating PD-1+CXCR3- CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. Immunity. 2013;39(4):758-769.
- Lucchini E, Zaja F, Bussel J.Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019? Haematologica. 2019;104(6):1124-1135.
- Zaja F, Volpetti S, Chiozzotto M, et al. . Longterm follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia. Am J Hematol. 2012;87(9):886-889.
- Bussel JB, Lee CS, Seery C, et al. . Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration. Haematologica. 2014;99(7):1264-1271.
- Choi PY-I, Roncolato F, Badoux X, Ramanathan S, Ho S-J, Chong BH. A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4). Blood. 2015; 126(4):500-503.
- Deshayes S, Khellaf M, Zarour A, et al. . Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: results at 5 years from the French prospective registry ITP-ritux. Am J Hematol. 2019;94(12):1314-1324.
- Kraaij T, Kamerling SWA, de Rooij ENM, et al. . The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus. J Autoimmun. 2018;91:45-54.
- Stasi R, Pagano A, Stipa E, Amadori S.Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood. 2001;98(4):952-957.
- Cooper N, Stasi R, Cunningham-Rundles S, et al. . The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol. 2004;125(2): 232-239.
- Arnold DM, Heddle NM, Carruthers J, et al. . A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia. Blood. 2012;119(6):1356-1362.
- Mei HE, Frölich D, Giesecke C, et al. . Steadystate generation of mucosal IgA+ plasmablasts is not abrogated by B-cell depletion therapy with rituximab. Blood. 2010;116(24):5181-5190.
- Liu Z, Davidson A.BAFF and selection of autoreactive B cells. Trends Immunol. 2011;32(8):388-394.
- Boneparth A, Woods M, Huang W, Akerman M, Lesser M, Davidson A.The effect of BAFF inhibition on autoreactive B cell selection in murine SLE. Mol Med. 2016;22:173-182.
- Ueno H, Banchereau J, Vinuesa CG. Pathophysiology of T follicular helper cells in humans and mice. Nat Immunol. 2015; 16(2):142-152.
- Heit A, Schmitz F, Gerdts S, et al. . Vaccination establishes clonal relatives of germinal center T cells in the blood of humans. J Exp Med. 2017;214(7):2139-2152.
- Coquery CM, Loo WM, Wade NS, et al. . BAFF regulates follicular helper t cells and affects their accumulation and interferon-γ production in autoimmunity. Arthritis Rheumatol. 2015;67(3):773-784.
- Goenka R, Matthews AH, Zhang B, et al. . Local BLyS production by T follicular cells mediates retention of high affinity B cells during affinity maturation. J Exp Med. 2014;211(1):45-56.
Source: PubMed